
|Articles|November 13, 2012
GALILEO: Aflibercept provides marked improvement in visual acuity in results from follow-up to 76 weeks
Intravitreal injection of aflibercept provides marked improvement in visual acuity in treatment-naive eyes with macular edema secondary to central retinal vein occlusion in results from follow-up to 76 weeks in the phase III GALILEO study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
5





















